ReviewMaterials today. Bio2026
Advancing precision tumor therapy: Progress in targeted delivery of peptide-based nanomaterials from microenvironment to organelles.
Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precisely targeted delivery of antitumor agents is a key strategy for enhancing cancer treatment efficacy. By leveraging specific tumor characteristics, functional modifications can construct highly selective delivery systems to optimize nanomedicine distribution at tumor sites. Owing to their editable sequences, peptides can be engineered into various targeting ligands for nanomaterial functionalization. Through specific receptor-ligand interactions, these modified nanomaterials achieve enhanced tumor-specific localization and deep penetration, enabling precise therapeutic agent delivery and improved treatment outcomes. This paper systematically reviews recent advances in peptide-based nanomaterials for tumor-targeted therapy. Based on molecular recognition, we present their applications in targeting the tumor microenvironment (TME) (including vasculature,immune cells, extracellular matrix, and associated fibroblasts), tumor cells, and organelles (such as mitochondria, endoplasmic reticulum [ER], Golgi apparatus, and nucleus). Furthermore, we provide an in-depth discussion of the opportunities and challenges these materials face in drug-targeted delivery, aiming to support the advancement of tumor-targeting nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.